Filter

Refine by collections

  • 100 years of Insulin and Glucagon (2)

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 2 of 2 items for :

  • gastroenteropancreatic x
  • 100 years of Insulin and Glucagon x
  • Refine by access: All content x
Clear All
Krystallenia I Alexandraki Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed Close
,
Gregory A Kaltsas Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed Close
, and
Simona Grozinsky-Glasberg Department of Endocrinology and Metabolism, Neuroendocrine Tumor Unit, ENETS Center of Excellence, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed Close

-DOTATATE with metastatic gastroenteropancreatic NENs (GEP-NENs), 2 had insulinomas; 1 achieved partial remission (PR) and the other PD post-therapy ( Kwekkeboom et al. 2005 ). Recently, it was shown that PRRT-induced symptomatic responses in 67% of patients

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0020
Volume/Issue:
Volume 30: Issue 9
Free access
Francesca Marini Fondazione FIRMO Onlus, Italian Foundation for the Research on Bone Diseases, Florence, Italy

Search for other papers by Francesca Marini in
Google Scholar
PubMed Close
,
Francesca Giusti Donatello Bone Clinic, Villa Donatello Hospital, Sesto Fiorentino, Italy

Search for other papers by Francesca Giusti in
Google Scholar
PubMed Close
, and
Maria Luisa Brandi Fondazione FIRMO Onlus, Italian Foundation for the Research on Bone Diseases, Florence, Italy
Donatello Bone Clinic, Villa Donatello Hospital, Sesto Fiorentino, Italy

Search for other papers by Maria Luisa Brandi in
Google Scholar
PubMed Close

, principally affecting parathyroid glands, neuroendocrine tissues of the gastro-entero-pancreatic tract, anterior pituitary, and adrenal cortical glands. MEN1 is caused by a germline heterozygous inactivating mutation of the MEN1 tumor-suppressor gene

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0245
Volume/Issue:
Volume 31: Issue 5
Restricted access